Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2022-01-04 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Director's Dealing 2022
Director's Dealing Classification · 100% confidence The document explicitly states it is disclosing transactions made by managerial employees and closely associated persons in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse. This regulation mandates the disclosure of insider trading or transactions by persons discharging managerial responsibilities (PDMRs). The content details the name, position, nature of the transaction ('Acquisition due to vesting of restricted stock units'), price, and volume for several executives (Jan van de Winkel, Judith Klimovsky, Anthony Pagano). This perfectly matches the definition of Director's Dealing (DIRS).
2022-01-04 English
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 100% confidence The document is a company announcement regarding transactions in shares and linked securities by managerial employees and their closely associated persons, specifically mentioning the vesting of restricted stock units. This falls under the category of Director's Dealing (DIRS), which covers reports of share transactions by company directors and executives.
2022-01-04 English
6-K
Foreign Filer Report
2021-12-15 English
6-K
Foreign Filer Report
2021-12-14 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory compliance with the Danish Capital Markets Act. This fits the definition of a 'Share Issue/Capital Change' (SHA) as it describes a specific change in the company's capital structure.
2021-12-14 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription price, and the impact on the total share capital. This falls under the category of share issuance and capital changes. While it mentions an attachment, the text itself provides the full details of the transaction, making it a primary announcement of a capital change rather than just a report publication announcement.
2021-12-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.